HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Can We Discontinue Betablockers after AMI?

Betablockers (BB) were the first drugs shown to effectively reduce events after acute MI. However, reperfusion and...
solaci -
Learn More
Other

Strategies to Reduce Acute Kidney Injury in Angioplasty

The title of this article leads us to think that we will find a list of things...
solaci -
Learn More
Antiplatelet

Aspirin, Bleeding and Cardiovascular Events in Healthy Elderly

The ASCEND and ARRIVE trials -presented at the European Cardiology Congress and published in The New England...
solaci -
Learn More
Other

AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure

Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly...
solaci -
Learn More
Other

AHA 2018 | New Dyslipidemia Guidelines Support Non-Statin Therapy and Coronary Artery Calcium Screening

While the guidelines do not recommend a specific treatment target, they suggest additional therapy in high-risk patients...
solaci -
Learn More
Other

AHA 2018 | No Benefits with Methothrexate as Anti-Inflammatory Drug

Low-dose methotrexate (a nonspecific anti-inflammatory agent used for the treatment of rheumatoid arthritis and other autoimmune disorders)...
solaci -
Learn More
Other

AHA 2018 | Canakinumab Reduces Hospitalization for Cardiac Failure in Respondents

The benefit was dose-dependent reduction, regardless the presence of absence of baseline cardiac failure. Patients with prior...
solaci -
Learn More
Antithrombotic Anticoagulants

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction...
solaci -
Learn More